← back to search

Seth J. Zost

Lawrence Livermore National Security · US
Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Influenza Virus Research Studies, Monoclonal and Polyclonal Antibodies Research, and Viral gastroenteritis research and epidemiology.
h-index
31
citations
8,959
works
70
NIH funding
primary concept
Biology
email

Recent publications

Computationally restoring the potency of a clinical antibody against Omicron
Nature 2024cited by 47position: middledoi
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Nature Medicine 2022cited by 764position: middledoi
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Nature Medicine 2021cited by 1,014position: middledoi
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Nature Microbiology 2021cited by 327position: middledoi
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Nature 2021cited by 260position: middledoi
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Cell Reports 2021cited by 112position: middledoi
An Egg-Derived Sulfated <i>N</i> -Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines
mBio 2021cited by 20position: middledoi
Potently neutralizing and protective human antibodies against SARS-CoV-2
Nature 2020cited by 1,190position: firstdoi
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Cell Host & Microbe 2020cited by 1,143position: middledoi
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Nature Medicine 2020cited by 539position: firstdoi
Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin
eLife 2019cited by 139position: middledoi
Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit
mBio 2019cited by 106position: middledoi
Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein–Based Influenza Vaccines During the 2017–2018 Season
Clinical Infectious Diseases 2019cited by 50position: middledoi
Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans
Cell Reports 2019cited by 35position: firstdoi
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
Nature Communications 2018cited by 282position: middledoi
Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains
Proceedings of the National Academy of Sciences 2017cited by 569position: firstdoi
Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season
Proceedings of the National Academy of Sciences 2014cited by 238position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Scott E. Hensley · Parker Institute for Cancer Immunotherapy8 papers (2014–2021)Patrick C. Wilson · University of Lethbridge5 papers (2014–2021)Kaela Parkhouse · California University of Pennsylvania5 papers (2014–2019)Jesse D. Bloom · Fred Hutch Cancer Center4 papers (2014–2020)James E. Crowe · Vanderbilt University Medical Center3 papers (2020–2022)Sarah Cobey · Ecologie & Evolution3 papers (2017–2021)Carole Henry · Université de Rouen Normandie2 papers (2019–2021)Megan E. Gumina · National Institute of Allergy and Infectious Diseases2 papers (2017–2019)Min Huang · China Agricultural University2 papers (2014–2021)Nai‐Ying Zheng · Cornell University2 papers (2014–2021)Robert H. Carnahan · Vanderbilt University Medical Center2 papers (2020–2021)Rachel E. Sutton · Vanderbilt University Medical Center2 papers (2020–2021)Juhye Lee · Metropolitan Research Institute2 papers (2019–2019)Rachel Eguia · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa2 papers (2019–2020)Pavlo Gilchuk · AstraZeneca (Japan)2 papers (2020–2021)Elad Binshtein · Vanderbilt University Medical Center2 papers (2020–2021)Naveenchandra Suryadevara · Vanderbilt University Medical Center2 papers (2020–2021)Michael Diamond · Infectious Disease Research Institute2 papers (2021–2022)Beth H. Shaz · Duke University1 papers (2014–2014)Nídia S. Trovão · National Institutes of Health1 papers (2019–2019)